<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903227</url>
  </required_header>
  <id_info>
    <org_study_id>NAI03</org_study_id>
    <secondary_id>EudraCT number: 2005-005557-22</secondary_id>
    <nct_id>NCT00903227</nct_id>
  </id_info>
  <brief_title>Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis</brief_title>
  <official_title>A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian J Lipworth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 40% of patients with asthma have allergic rhinitis and treatment of nasal airway
      inflammation with topical steroids improves the twitchiness of the airways
      (hyperresponsiveness) and overall asthma control. The use of inhaled corticosteroids reduces
      symptoms, severity of asthma attacks, improves quality of life, and reduces asthma related
      deaths. Similarly, treatment of rhinitis with nasal steroids reduces symptoms and improves
      quality of life. While there is evidence that combined treatment of the nose and the lungs
      with topical steroids improves symptoms and underlying inflammation, it is unclear whether
      such control can be achieved using a smaller dose of inhaled steroid in combination with
      nasal steroid. It is therefore the intention of this study to evaluate if combination steroid
      therapy (nose and lungs) has a steroid sparing effect in patients with asthma and rhinitis
      using sensitive markers of airway inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>methacholine PC20</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Juniper AQLQ</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractionated Nitric Oxide</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ECP</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood eosinophils</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight urinary cortisol creatinine</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow rate</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Nitric Oxide</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Juniper mini RQLQ</measure>
    <time_frame>0, 2, 4, 6, 8, 10, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Evohaler pMDI</intervention_name>
    <description>One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 puff of inhaled Placebo twice a day</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Evohaler</intervention_name>
    <description>One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo intranasal spray</intervention_name>
    <description>placebo intranasal spray 2 squirts each nostril once a day</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate (Flixonase®)</intervention_name>
    <description>intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts</description>
    <arm_group_label>Combined</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate atopic asthmatics with FEV1 ≥ 60% on ≤ 1000 ug BDP and concomitant
             persistent allergic rhinitis (SPT +ve and PC20 &lt; 4 mg/ml)

          -  Male or female aged 18-65 years

          -  Informed Consent

          -  Ability to comply with the requirements of the protocol

        Exclusion Criteria:

          -  Severe asthmatics as defined by an FEV1 ≤ 60% or PEF variability &gt; 30% or with
             continual daytime or nocturnal symptoms.

          -  Nasal Polyposis grade 2/3, deviated nasal septum ≥ 50%

          -  The use of oral corticosteroids within the last 3 months

          -  Recent respiratory tract infection (2 months)

          -  Significant concomitant respiratory disease

          -  Any other significant medical condition or investigation which may jeopardise the
             safety of the participant or the conduct of the protocol

          -  Any significant abnormal laboratory result as deemed by the investigators

          -  Pregnancy, planned pregnancy or lactation

          -  Known or suspected contra-indication to any of the IMP's

          -  Concomitant use of medicines (prescribed, over the counter or herbal) that may
             interfere with the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Nair, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Lipworth, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol. 1997 Feb;99(2):S781-6. Review.</citation>
    <PMID>9042071</PMID>
  </reference>
  <reference>
    <citation>Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol. 1988 May;81(5 Pt 2):1042-7.</citation>
    <PMID>3131406</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Nielsen LP, Kips J, Foresi A, Cauwenberge P, Tudoric N, Howarth P, Richards DH, Williams M, Pauwels R; SPIRA Study Group. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy. 2005 Jul;60(7):875-81.</citation>
    <PMID>15932376</PMID>
  </reference>
  <reference>
    <citation>Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P, Denburg J, Fokkens WJ, Grouse L, Mullol K, Ohta K, Schermer T, Valovirta E, Zhong N, Zuberbier T. Allergic rhinitis management pocket reference 2008. Allergy. 2008 Aug;63(8):990-6. doi: 10.1111/j.1398-9995.2008.01642.x.</citation>
    <PMID>18691301</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Brian J Lipworth</investigator_full_name>
    <investigator_title>Professor (Clinical) Airway allergy and COPD</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Allergic rhinitis</keyword>
  <keyword>fluticasone</keyword>
  <keyword>methacholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

